These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12425151)

  • 21. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
    Garlapati K; Kammari A; Badam RK; B E S; Boringi M; Soni P
    Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):312-318. PubMed ID: 30932714
    [No Abstract]   [Full Text] [Related]  

  • 22. Parotid irrigation and cevimeline gargle for treatment of xerostomia in Sjögren's syndrome.
    Takagi Y; Katayama I; Tashiro S; Nakamura T
    J Rheumatol; 2008 Nov; 35(11):2289-91. PubMed ID: 19004065
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome.
    Noaiseh G; Baker JF; Vivino FB
    Clin Exp Rheumatol; 2014; 32(4):575-7. PubMed ID: 25065774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.
    Brimhall J; Jhaveri MA; Yepes JF
    Spec Care Dentist; 2013; 33(3):123-7. PubMed ID: 23600983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cevimeline on salivary components in patients with Sjögren syndrome.
    Suzuki K; Matsumoto M; Nakashima M; Takada K; Nakanishi T; Okada M; Ohsuzu F
    Pharmacology; 2005 May; 74(2):100-5. PubMed ID: 15722648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren's Syndrome.
    Yasuda H; Niki H
    Clin Drug Investig; 2002; 22(2):67-73. PubMed ID: 23315394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of pilocarpine and cevimeline on salivary flow.
    Braga MA; Tarzia O; Bergamaschi CC; Santos FA; Andrade ED; Groppo FC
    Int J Dent Hyg; 2009 May; 7(2):126-30. PubMed ID: 19416095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cevimeline enhances the excitability of rat superior salivatory neurons.
    Ueda H; Mitoh Y; Ichikawa H; Kobashi M; Yamashiro T; Matsuo R
    J Med Invest; 2009; 56 Suppl():267-9. PubMed ID: 20224198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.
    Ono K; Inagaki T; Iida T; Wakasugi-Sato N; Hosokawa R; Inenaga K
    Arch Oral Biol; 2012 Apr; 57(4):421-8. PubMed ID: 22099058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapy of Sjogren's syndrome: a review.
    Coaccioli S; Giuliani M; Puxeddu A
    Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cevimeline on excitability of parasympathetic preganglionic neurons in the superior salivatory nucleus of rats.
    Mitoh Y; Ueda H; Ichikawa H; Fujita M; Kobashi M; Matsuo R
    Auton Neurosci; 2017 Sep; 206():1-7. PubMed ID: 28600120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Artificial saliva products and drugs to treat xerostomia.
    Wynn RL; Meiller TF
    Gen Dent; 2000; 48(6):630-6. PubMed ID: 12004654
    [No Abstract]   [Full Text] [Related]  

  • 33. Correlation between salivary secretion and salivary AQP5 levels in health and disease.
    Wang D; Iwata F; Muraguchi M; Ooga K; Ohmoto Y; Takai M; Mori T; Ishikawa Y
    J Med Invest; 2009; 56 Suppl():350-3. PubMed ID: 20224222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cevimeline gargle for the treatment of xerostomia in patients with Sjögren's syndrome.
    Takagi Y; Kimura Y; Nakamura T
    Ann Rheum Dis; 2004 Jun; 63(6):749. PubMed ID: 15140789
    [No Abstract]   [Full Text] [Related]  

  • 35. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations.
    von Bültzingslöwen I; Sollecito TP; Fox PC; Daniels T; Jonsson R; Lockhart PB; Wray D; Brennan MT; Carrozzo M; Gandera B; Fujibayashi T; Navazesh M; Rhodus NL; Schiødt M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S57.e1-15. PubMed ID: 17379156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological approaches to targeting muscarinic acetylcholine receptors.
    Matera C; Tata AM
    Recent Pat CNS Drug Discov; 2014; 9(2):85-100. PubMed ID: 25413004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.
    Han M; Lian J; Su Y; Deng C
    J Psychopharmacol; 2022 Feb; 36(2):202-213. PubMed ID: 34694173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salivary gland ultrasonography as a primary imaging tool for predicting efficacy of xerostomia treatment in patients with Sjögren's syndrome.
    Takagi Y; Sumi M; Nakamura H; Sato S; Kawakami A; Nakamura T
    Rheumatology (Oxford); 2016 Feb; 55(2):237-45. PubMed ID: 26338664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approaches to the treatment of Sjögren's syndrome.
    Fox RI; Michelson P
    J Rheumatol Suppl; 2000 Dec; 61():15-21. PubMed ID: 11128699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a muscarinic M3 receptor agonist on gastric motility.
    Chiba T; Kudara N; Sato M; Inomata M; Orii S; Suzuki K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2039-41. PubMed ID: 17914991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.